These phenotypes mirror the metabolic profiles described for MYC-driven SCLC and are marked by high asparagine, arginine, and polyamine flux, as well as hyperactive mTOR signaling—all contributing to relentless proliferative and metastatic gain. The gene discussed is MTOR; the disease is small cell lung carcinoma.